{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "related-to", "type": "clause", "offset": [46, 56]}, {"key": "appendix-4", "type": "definition", "offset": [102, 112]}], "snippet": "means the set of validated analytical methods related to the Manufacturing of the API as set forth on Appendix 4 hereto.", "samples": [{"hash": "6L514g6me7u", "uri": "/contracts/6L514g6me7u#analytical-methods", "label": "Commercial Supply Agreement (Amag Pharmaceuticals Inc.)", "score": 29.9691991786, "published": true}, {"hash": "d3M8nfUxYaA", "uri": "/contracts/d3M8nfUxYaA#analytical-methods", "label": "Commercial Supply Agreement (Amag Pharmaceuticals Inc.)", "score": 29.5859000684, "published": true}, {"hash": "aLnDWolhatj", "uri": "http://ir.amagpharma.com/static-files/59e7c5d7-4068-4ce4-ad3b-3f97ed2ec605", "label": "Amendment", "score": 14.1704312115, "published": false}], "size": 4, "hash": "2d14ffbfe882dcdf71775a799a21eb91", "id": 1}, {"snippet_links": [{"key": "the-foregoing", "type": "definition", "offset": [215, 228]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [361, 385]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [387, 413]}, {"key": "licensed-know", "type": "definition", "offset": [460, 473]}, {"key": "without-limiting-section", "type": "clause", "offset": [479, 503]}], "snippet": "means analytical methods and test protocols which may be useful to measure composition and properties (e.g., physical, mechanical, thermal, viscoelastic, viscometric, spectroscopic, etc., including modifications of the foregoing analytical methods and test protocols) used by CHEMOURS TT or CHEMOURS FC or otherwise in CHEMOURS TT\u2019s or CHEMOURS FC\u2019s possession as of the Effective Date. For the avoidance of doubt, all Analytical Methods shall be deemed to be Licensed Know-How (without limiting Section 2.4(b)).", "samples": [{"hash": "9RpUKFE5yqf", "uri": "/contracts/9RpUKFE5yqf#analytical-methods", "label": "Intellectual Property Cross License Agreement", "score": 31.340862423, "published": true}, {"hash": "hQODsmzev27", "uri": "/contracts/hQODsmzev27#analytical-methods", "label": "Intellectual Property Cross License Agreement (Chemours Co)", "score": 26.4948665298, "published": true}, {"hash": "dBkpAsiodJ5", "uri": "/contracts/dBkpAsiodJ5#analytical-methods", "label": "Intellectual Property Cross License Agreement (Chemours Company, LLC)", "score": 26.3004791239, "published": true}], "size": 3, "hash": "f0282f8d9e8985ab18d735c521446ad1", "id": 2}, {"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "collaboration-product", "type": "definition", "offset": [25, 46]}, {"key": "bulk-drug", "type": "definition", "offset": [130, 139]}, {"key": "the-applicable", "type": "clause", "offset": [177, 191]}], "snippet": "means, with respect to a Collaboration Product, a comprehensive set of analytical methods used to test the quality of in-process, bulk drug substance(s) and drug product(s) for the applicable Collaboration Product.", "samples": [{"hash": "1MWRLkuaoOQ", "uri": "/contracts/1MWRLkuaoOQ#analytical-methods", "label": "Joint Development and License Agreement", "score": 31.340862423, "published": true}, {"hash": "j5UZifGUCDW", "uri": "/contracts/j5UZifGUCDW#analytical-methods", "label": "Joint Development and License Agreement (Pfenex Inc.)", "score": 25.4791238877, "published": true}, {"hash": "fIzfWBeW6Gk", "uri": "/contracts/fIzfWBeW6Gk#analytical-methods", "label": "Joint Development and License Agreement (Pfenex Inc.)", "score": 25.3394934976, "published": true}], "size": 3, "hash": "c01f2eae9f9d086504378e8b246a31b4", "id": 3}, {"snippet_links": [{"key": "a-sample", "type": "definition", "offset": [72, 80]}, {"key": "laboratory-testing", "type": "definition", "offset": [104, 122]}], "snippet": "means defined protocols for the analysis of the presence of a HPCCCH in a sample of a medium, including laboratory testing that can be described and is readily reproducible by another party.\u00b6", "samples": [{"hash": "6qulkzPCejg", "uri": "https://www.oregon.gov/oha/PH/HEALTHYENVIRONMENTS/HEALTHYNEIGHBORHOODS/TOXICSUBSTANCES/Documents/333-016_Notice%20of%20Proposed%20Rulemaking.pdf", "label": "www.oregon.gov", "score": 8.2361396304, "published": false}, {"hash": "1Rv7rL7MbAZ", "uri": "https://members.wto.org/crnattachments/2020/TBT/USA/20_3886_00_e.pdf", "label": "members.wto.org", "score": 8.2361396304, "published": false}], "size": 3, "hash": "5067eb6fccba655315358432290e62f6", "id": 4}, {"snippet_links": [{"key": "related-to", "type": "clause", "offset": [46, 56]}, {"key": "by-company", "type": "clause", "offset": [104, 114]}, {"key": "if-applicable", "type": "clause", "offset": [129, 142]}, {"key": "materials-supplied", "type": "clause", "offset": [167, 185]}, {"key": "to-the-company", "type": "clause", "offset": [194, 208]}], "snippet": "means the set of validated analytical methods related to the Manufacturing of the Excipient as provided by Company to SAFC, and, if applicable, methods related to Raw Materials supplied by SAFC to the Company.", "samples": [{"hash": "8fX9XHyCpsX", "uri": "/contracts/8fX9XHyCpsX#analytical-methods", "label": "Commercial Supply Agreement (Heron Therapeutics, Inc. /De/)", "score": 27.9760438056, "published": true}, {"hash": "lE2u4XGK53k", "uri": "https://ir.herontx.com/static-files/9d262e02-1850-492d-baa0-dd67bb3d089b", "label": "ir.herontx.com", "score": 9.9623545517, "published": false}], "size": 3, "hash": "b05bda20d4b779e44101009317fe0efc", "id": 5}, {"snippet_links": [{"key": "chemical-of-concern", "type": "definition", "offset": [76, 95]}, {"key": "a-sample", "type": "definition", "offset": [129, 137]}, {"key": "laboratory-testing", "type": "definition", "offset": [161, 179]}], "snippet": "means defined protocols for the analysis of the presence of a high priority chemical of concern to children's health (HPCCCH) in a sample of a medium, including laboratory testing that can be described and is readily reproducible by another party.\u00b6", "samples": [{"hash": "d2Y4MXDy8EJ", "uri": "https://www.oregon.gov/oha/PH/HEALTHYENVIRONMENTS/HEALTHYNEIGHBORHOODS/TOXICSUBSTANCES/Documents/PH_119-2024TrackedChanges.pdf", "label": "www.oregon.gov", "score": 19.7354754056, "published": false}, {"hash": "cy2A6W4jOKk", "uri": "https://www.oregon.gov/oha/PH/HEALTHYENVIRONMENTS/HEALTHYNEIGHBORHOODS/TOXICSUBSTANCES/Documents/333-016%20Notice%20of%20Proposed%20Rulemaking%2010.31.2024.pdf", "label": "www.oregon.gov", "score": 17.518087395, "published": false}], "size": 2, "hash": "6fa991dbad1663c9b48df680d0c5bf13", "id": 6}, {"snippet_links": [{"key": "related-to", "type": "clause", "offset": [46, 56]}, {"key": "by-company", "type": "clause", "offset": [103, 113]}, {"key": "on-behalf-of", "type": "clause", "offset": [128, 140]}], "snippet": "means the set of validated analytical methods related to the Manufacturing of the SGD-1006 as provided by Company, or developed on behalf of Company, by SAFC.", "samples": [{"hash": "2RGc0aUzJ5F", "uri": "/contracts/2RGc0aUzJ5F#analytical-methods", "label": "Commercial Supply Agreement", "score": 31.340862423, "published": true}, {"hash": "iHZQUXibcE0", "uri": "/contracts/iHZQUXibcE0#analytical-methods", "label": "Commercial Supply Agreement (Seattle Genetics Inc /Wa)", "score": 22.839835729, "published": true}], "size": 2, "hash": "45d42bf7247723263ad883486d715b86", "id": 7}, {"snippet_links": [{"key": "the-foregoing", "type": "definition", "offset": [217, 230]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [363, 387]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [389, 415]}, {"key": "licensed-know", "type": "definition", "offset": [462, 475]}, {"key": "without-limiting-section", "type": "clause", "offset": [481, 505]}], "snippet": "means analytical methods and test protocols which may be useful to measure composition and properties ( e.g. , physical, mechanical, thermal, viscoelastic, viscometric, spectroscopic, etc., including modifications of the foregoing analytical methods and test protocols) used by CHEMOURS TT or CHEMOURS FC or otherwise in CHEMOURS TT\u2019s or CHEMOURS FC\u2019s possession as of the Effective Date. For the avoidance of doubt, all Analytical Methods shall be deemed to be Licensed Know-How (without limiting Section 2.4(b)).", "samples": [{"hash": "4Jq0bW1Yyjn", "uri": "http://d1lge852tjjqow.cloudfront.net/CIK-0001627223/8b68dc45-8d8d-409c-acd8-381e2720fd02.rtf", "label": "d1lge852tjjqow.cloudfront.net", "score": 10.1704312115, "published": false}], "size": 1, "hash": "0c9296125d7ee9e5e639e181f97052d7", "id": 8}, {"snippet_links": [{"key": "related-to", "type": "clause", "offset": [51, 61]}, {"key": "manufacturing-of-product", "type": "clause", "offset": [66, 90]}, {"key": "appendix-2", "type": "definition", "offset": [126, 136]}], "snippet": "means the set of SAFC validated analytical methods related to the Manufacturing of Product as set forth and referenced within Appendix 2.", "samples": [{"hash": "cm4kHjSbs2R", "uri": "/contracts/cm4kHjSbs2R#analytical-methods", "label": "Commercial Supply Agreement (Amag Pharmaceuticals Inc.)", "score": 23.8501026694, "published": true}], "size": 1, "hash": "b17adb2f8526b98f88b11b740adde5de", "id": 9}, {"snippet_links": [{"key": "agreement-for", "type": "clause", "offset": [52, 65]}, {"key": "determination-of-the", "type": "clause", "offset": [70, 90]}, {"key": "quality-of-the-goods", "type": "clause", "offset": [91, 111]}], "snippet": "means the analytical methods (if any) stated in the Agreement for the determination of the quality of the Goods.", "samples": [{"hash": "5xOdf72CKCf", "uri": "https://cdn.nufarm.com/wp-content/uploads/2018/10/11115129/Nufarm-Purchase-T-C.pdf", "label": "cdn.nufarm.com", "score": 5.8637919233, "published": false}], "size": 1, "hash": "2be0bae9d74b67e77d49af0f0c0db13e", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIbYW5hbHl0aWNhbC1tZXRob2RzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Analytical Methods", "snippet": "means the set of validated analytical methods related to the Manufacturing of the API as set forth on Appendix 4 hereto.", "size": 27, "id": "analytical-methods", "examples": ["Once transferred to Agila, neither Party shall make any changes to the Manufacturing Process, Specifications, <strong>Analytical Methods</strong>, Facility, Raw Materials or any other item in any manner that would reasonably cause any Collaboration Product for use in any clinical studies not to comply with the Specifications therefor or Applicable Laws, without the JSC\u2019s prior written approval.", "All Analytical Services, <strong>Analytical Methods</strong>, Analytical Results and related information&#x27;s herewith are considered confidential.", "The invoice must also include designation of the project and the operational program from which the supply is funded, specifically the wording: &quot;Centre of Accelerators and Nuclear <strong>Analytical Methods</strong> (CANAM) - OP, Reg.", "If during the course of this Agreement, a change in Specifications, Production Scale or <strong>Analytical Methods</strong> is requested by Corcept (for example due to regulatory agency request) the Parties will mutually evaluate the potential effect of such change on the Product to any <strong>Analytical Methods</strong> and the CMR.", "Invoice 2 must contain the information on funding from the Operational Program of Research, Development and Education within the project &quot;Centre of Accelerators and Nuclear <strong>Analytical Methods</strong> - OP&quot;, project registration number CZ.02.1.01 / 0.0 / 0.0 / 16_013 / 0001812.", "For Substandard risks issued at table ratings, multiply the above rates by the appropriate mortality factor.", "Regulatory Clinical Quality Assurance Quality Control <strong>Analytical Methods</strong> Validation Manufacturing Process Development Tech Services Manufacturing Equipment \u2013 Engineering and Validation Process Validation Each Party may, by providing written notice to the other Party, designate another qualified person to replace the above personnel.", "A formally approved document listing the tests, <strong>Analytical Methods</strong> and acceptance criteria specific to material.", "Corcept shall indemnify and hold harmless PharmaForm for any action or activity of such representatives while on PharmaForm\u2019s premises, that causes any change or modification to <strong>Analytical Methods</strong> or CMRs resulting in any deviation, NCE or investigation or that results in any injury or damage to person or property, except to the extent arising from PharmaForm\u2019s negligence or breach of this Agreement.", "With respect to Additional Lead Products, \u201cReformulated Products\u201d are defined as Additional Products that yield a maximum result of 1.0 microgram (\u201c\u00b5g\u201d) residual lead content by weight on any surface sampled pursuant to the NIOSH 9100 sampling protocol and analyzed pursuant to EPA <strong>Analytical Methods</strong> 3050B and/or 6010B, and that contain a maximum of 100 parts per million (\u201cppm\u201d) (0.01%) lead by weight."], "related": [["processes", "Processes", "Processes"], ["protocols", "Protocols", "Protocols"], ["manufacturing-process", "Manufacturing Process", "Manufacturing Process"], ["api", "API", "API"], ["sops", "SOPs", "SOPs"]], "related_snippets": [], "updated": "2025-07-07T00:16:46+00:00"}, "json": true, "cursor": ""}}